Journal
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
Volume 18, Issue 12, Pages 1588-1591Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jvir.2007.08.015
Keywords
-
Ask authors/readers for more resources
Yttrium-90 microspheres have been recently approved by the Food and Drug Administration and have become available to physicians in the United States for the treatment of hepatic neoplasia. Published results regarding the benefits of Y-90 radioembolotherapy within the rapidly evolving landscape of systemic therapies for advanced unresectable colorectal cancer are limited. In that context, outcomes in patients who have received the recently approved biologic agents bevacizumab and cetuximab in addition to chemotherapy are unknown. This report briefly describes the authors' treatment experience with this cohort of patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available